|Bid||1.3300 x 1000|
|Ask||1.3400 x 2200|
|Day's range||1.2700 - 1.3400|
|52-week range||1.2600 - 46.0500|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||12 May 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||2.88|
If you require any further assistance, I would now like to hand the conference over to your host today, Carrie Mendivil from investor relations. Earlier today, Zymergen released preliminary substantial results for the quarter ended March 31, 2022. Joining me today from Zymergen are Jay Flatley, acting chief executive officer, and Ena Singh, chief financial officer.
Zymergen (ZY) delivered earnings and revenue surprises of 1.41% and 57.08%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
EMERYVILLE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Biotechnology company Zymergen Inc. (“Zymergen” or the “Company”), today reported preliminary financial results for the first quarter ended March 31, 2022. “Our mission at Zymergen is to partner with nature to make better products, a better way, for a better world. One of the key transformations we have made is to create a nimble, disciplined product development process,” said Zymergen’s interim CEO, Jay Flatley. “We now have the infrastructur